Friday, 16 October 2026European Markets

ODFJELL SER. B Stock Bullish Momentum With A 20% Jump In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of ODFJELL SER. B (Oslo Børs All-share Index_GI: ODFB.OL) rose by a staggering 20.61% in 10 sessions from kr82.5 to kr99.50 at 16:40 EST on Tuesday, following the last session's upward trend. Oslo Børs All-share Index_GI is sliding 0.35% to kr1,410.94, after five consecutive sessions in a row of losses.

About ODFJELL SER. B

Odfjell SE engages in the transportation and storage of bulk liquid chemicals, acids, edible oils, and other special products. The company operates Chemical Tankers and Tank Terminals segments. It owns and operates chemical tankers that offers global and regional transportation; and tank terminals, which provides storage of various chemical and petroleum products. As of December 31, 2021, it operated a chemical tanker fleet of 93 vessels, including 50 owned, six bareboat chartered, 13 time chartered vessels, and 24 pool vessels. The company's terminal network comprises of 469 tanks with 1.3 million cubic meters of storage capacity. It operates in Norway, the Netherlands, rest of Europe, North America, South America, the Middle East, Asia, Australasia, and Africa. Odfjell SE was founded in 1914 and is headquartered in Bergen, Norway.

Earnings Per Share

As for profitability, ODFJELL SER. B has a trailing twelve months EPS of kr2.93.

PE Ratio

ODFJELL SER. B has a trailing twelve months price to earnings ratio of 33.91. Meaning, the purchaser of the share is investing kr33.91 for every norwegian krone of annual earnings.

Volatility

ODFJELL SER. B's last week, last month's, and last quarter's current intraday variation average was 0.35%, 0.67%, and 1.79%.

ODFJELL SER. B's highest amplitude of average volatility was 3.63% (last week), 1.96% (last month), and 1.79% (last quarter).

More news about ODFJELL SER. B (ODFB.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com